As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Century Therapeutics, Inc. The largest reported stake is Chen Yu's, at 9.9%. 10 filings are on record since November 14, 2025 (Schedule 13G, January 15, 2026).
Sell to companies like Century Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Point72 Asset Management, L.P. · Percent: 3.3% · SCHEDULE 13G/A
- · Holder: RTW Investments, LP · Percent: 7.1% · SCHEDULE 13G
- · Holder: Point72 Asset Management, L.P. · Percent: 6.8% · SCHEDULE 13G/A
- · Holder: RA Capital Management, L.P. · Percent: 9.9% · SCHEDULE 13G
- · Holder: Venrock Healthcare Capital Partners III, L.P. · Percent: 7.1% · SCHEDULE 13G
Century Therapeutics, Inc. has 10 Schedule 13D or 13G filings on record since 2025-11-14. 6 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.9% | 17,754,430 | SCHEDULE 13G, 2026-01-15 | 2026-01-09 | |
| RA Capital Management, L.P. | 9.9% | 17,944,649 | SCHEDULE 13G, 2026-01-16 | 2026-01-09 |
| Deep Track Capital, LP | 7.34% | 13,486,400 | SCHEDULE 13G, 2026-01-15 | 2026-01-08 |
| Venrock Healthcare Capital Partners III, L.P. | 7.1% | 13,043,478 | SCHEDULE 13G, 2026-01-16 | 2026-01-09 |
| Commodore Capital LP | 7.1% | 13,043,478 | SCHEDULE 13G, 2026-01-16 | 2026-01-09 |
| RTW Investments, LP | 7.1% | 13,043,478 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Bain Capital Life Sciences Opportunities III, LP | 4.1% | 3,538,609 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Point72 Asset Management, L.P. | 3.3% | 5,964,678 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Century Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Century Therapeutics, Inc. and the records around it.
Century Therapeutics, Inc. elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- Bain Capital Life Sciences Opportunities III, LP also filed stake reports on 2 other companies: CABALETTA BIO, INC. (Aug 2026), KYVERNA THERAPEUTICS, INC. (Aug 2026)
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Century Therapeutics, Inc.
Get an email when Century Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Century Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Century Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Century Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-11-14 | Bain Capital Life Sciences Opportunities III, LP | 4.1% | SCHEDULE 13G/A |
| 2026-01-05 | Point72 Asset Management, L.P. | 5.4% | SCHEDULE 13G |
| 2026-01-15 | Deep Track Capital, LP | 7.34% | SCHEDULE 13G |
| 2026-01-15 | Chen Yu | 9.9% | SCHEDULE 13G |
| 2026-01-16 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2026-01-16 | Venrock Healthcare Capital Partners III, L.P. | 7.1% | SCHEDULE 13G |
| 2026-01-16 | Commodore Capital LP | 7.1% | SCHEDULE 13G |
| 2026-02-17 | Point72 Asset Management, L.P. | 6.8% | SCHEDULE 13G/A |
| 2026-05-15 | Point72 Asset Management, L.P. | 3.3% | SCHEDULE 13G/A |
| 2026-05-15 | RTW Investments, LP | 7.1% | SCHEDULE 13G |
Questions about who owns Century Therapeutics, Inc.
Who owns Century Therapeutics, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Century Therapeutics, Inc.: Chen Yu (9.9%, Schedule 13G, filed 2026-01-15), RA Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-01-16), Deep Track Capital, LP (7.34%, Schedule 13G, filed 2026-01-15), Venrock Healthcare Capital Partners III, L.P. (7.1%, Schedule 13G, filed 2026-01-16) and Commodore Capital LP (7.1%, Schedule 13G, filed 2026-01-16); 1 more is listed above.
Who are the largest shareholders of Century Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Century Therapeutics, Inc. on this page are Chen Yu (9.9%), RA Capital Management, L.P. (9.9%) and Deep Track Capital, LP (7.34%).
When did Chen Yu buy into Century Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Chen Yu on this page is the Schedule 13G, filed 2026-01-15, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Century Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 9, 2026 | Leadership change: Joseph Truitt appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Century Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.